Composition Development and Experimental Study of the Liposomal form of an Antiarrhythmic Drug

• Published in: Pharmaceutical chemistry journal Vol. 56; no. 8; pp. 1064 - 1069
• Main Authors: Uzbekov, V. V., Abdullaev, B. F., Ziyavitdinov, Zh. F., Ishimov, U. Zh, Berdiev, N. Sh, Oshchepkova, Yu. I., Salikhov, Sh. I.
• Format: Journal Article
• Language: English
• Published: New York Springer US 01.11.2022; Springer
• Subjects: Anti-arrhythmia drugs; Biological products; Medicine; Organic Chemistry; Pharmacology/Toxicology; Pharmacy; liposomal form; artificial blood serum; monoammonium salt of glycyrrhizic acid; antiarrhythmic drugs; lappaconitine hydrobromide; cardiovascular diseases; Allapinin
• ISSN: 0091-150X; 1573-9031
• DOI: 10.1007/s11094-022-02754-4

The aim of the work was to obtain a liposomal form of the complex of the antiarrhythmic drug allapinin (lappaconitine hydrobromide) and the monoammonium salt of glycyrrhizic acid (MASGA) and to study the release kinetics of allapinin/MASGA into a medium modeling the salt composition and pH of blood serum. As a result, liposomes containing the allapinin/MASGA complex were obtained. The most preferred ratio of phosphatidylcholine and cholesterol in the liposomes was found to be 5:2. The release kinetics of the lappaconitine hydrobromide/MASGA complex from the liposomes were studied in a medium simulating the salt composition and pH of blood serum [1.5 mMsodium phosphate (pH 7.4) + 0.15MNaCl] and showed that 32% of lappaconitine was released in the first 30 min. The release rate stabilized within 2 h after administration and practically did not drop in the next 3 h of the experiment. This behavior showed good prospects for using liposomes loaded with the allapinin/MASGA complex as a prolonged release drug form.